Daniel R Wahl
Overview
Explore the profile of Daniel R Wahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1996
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paradis K, Mayo C, Matrosic C, Prisciandaro J, Rosen B, Allen S, et al.
Int J Radiat Oncol Biol Phys
. 2025 Mar;
PMID: 40068779
Introduction: Reirradiation (reRT) has become increasingly prevalent due to an aging population and advancements in cancer detection and treatment. However, the field is still lacking standardized dosimetric evaluation methods and...
2.
Kim M, Aryal M, Suresh K, Rosen B, Parmar H, You D, et al.
Int J Radiat Oncol Biol Phys
. 2025 Mar;
PMID: 40058709
Background: Biologically-informed radiotherapy (RT) targeting an adversely prognostic hypercellular/hyperperfused imaging phenotype in patients with newly diagnosed glioblastoma (GBM) may improve outcomes by identifying emerging regions of treatment resistance associated with...
3.
Valvo V, Zhang Q, Jiang L, Holcomb E, Pearson A, Edmunds A, et al.
Mol Cancer Ther
. 2024 Dec;
:OF1-OF16.
PMID: 39688341
PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)-mediated antitumoral...
4.
Korimerla N, Meghdadi B, Haq I, Wilder-Romans K, Xu J, Becker N, et al.
bioRxiv
. 2024 Dec;
PMID: 39651281
Glioblastoma (GBM) is uniformly lethal due to profound treatment resistance. Altered cellular metabolism is a key mediator of GBM treatment resistance. Uptake of the essential sulfur-containing amino acid methionine is...
5.
Mbah N, Myers A, Sajjakulnukit P, Chung C, Thompson J, Hong H, et al.
Nat Commun
. 2024 Oct;
15(1):8983.
PMID: 39419964
H3K27M diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), exhibit cellular heterogeneity comprising less-differentiated oligodendrocyte precursors (OPC)-like stem cells and more differentiated astrocyte (AC)-like cells. Here, we establish...
6.
Elaimy A, El-Derany M, James J, Wang Z, Pearson A, Holcomb E, et al.
JCI Insight
. 2024 Sep;
9(21).
PMID: 39287988
End-stage liver disease is marked by portal hypertension, systemic elevations in ammonia, and development of hepatocellular carcinoma (HCC). While these clinical consequences of cirrhosis are well described, it remains poorly...
7.
Guo Y, Li Z, Parsels L, Wang Z, Parsels J, Dalvi A, et al.
bioRxiv
. 2024 Sep;
PMID: 39253432
Background: Radiotherapy (RT) is the primary treatment for diffuse midline glioma (DMG), a lethal pediatric malignancy defined by histone H3 lysine 27-to-methionine (H3K27M) mutation. Based on the loss of H3K27...
8.
Pathak A, Palasalava S, Knott M, Colon B, Ciervo E, Zhou Y, et al.
bioRxiv
. 2024 Aug;
PMID: 39091833
Sex differences in immune responses impact cancer outcomes and treatment response, including in glioblastoma (GBM). However, host factors underlying sex specific immune-cancer interactions are poorly understood. Here, we identify the...
9.
Peterson E, Sajjakulnukit P, Scott A, Heaslip C, Andren A, Wilder-Romans K, et al.
Cancer Metab
. 2024 Apr;
12(1):11.
PMID: 38594734
Background: Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are a fatal form of brain cancer. These tumors often carry a driver mutation on histone H3 converting lysine...
10.
Zhang Q, Jiang L, Wang W, Huber A, Valvo V, Jungles K, et al.
JCI Insight
. 2024 Feb;
9(6).
PMID: 38376927
Radiotherapy induces a type I interferon-mediated (T1IFN-mediated) antitumoral immune response that we hypothesized could be potentiated by a first-in-class ataxia telangiectasia mutated (ATM) inhibitor, leading to enhanced innate immune signaling,...